Inhibition of PGE(2)/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress

The platinum-based chemotherapeutic agent, oxaliplatin, is used to treat advanced colorectal cancer (CRC). Unfortunately, nearly all patients acquire resistance to oxaliplatin after long-term use, limiting its therapeutic efficacy. Since COX-2 and PGE(2) signaling can impact colon cancer cell prolif...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huakang, Aladelokun, Oladimeji, Ideta, Takayasu, Giardina, Charles, Ellis, Lee M., Rosenberg, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427013/
https://www.ncbi.nlm.nih.gov/pubmed/30894570
http://dx.doi.org/10.1038/s41598-019-40848-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427013/
https://www.ncbi.nlm.nih.gov/pubmed/30894570
http://dx.doi.org/10.1038/s41598-019-40848-4

Ejemplares similares